Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion

Lawrence Mandarino, Debra Stenner, Wayne Blanchard, Steven Nissen, John Gerich, Nicholas Ling, Paul Brazeau, Peter Bohlen, Frederick Esch, Roger Guillemin

    Research output: Contribution to journalArticle

    164 Scopus citations

    Abstract

    The widely occurring1-3 tetradecapeptide somatostatin (SRIF-14) has been variously implicated4-8 as a neurotransmitter, a neurohormone, a cybernin (local regulatory factor) and a hormone. In the first isolation of SRIF-14 from hypothalamic extracts9,10 and subsequent extracts of other tissues11-15, peptides of higher molecular weight but with similar activity have been noted. Recently two such peptides have been characterized as the 28-amino acid SRIF-28 (from porcine gastro-intestinal tract16 and porcine and ovine hypothalamus17,18) and the 25-amino acid SRIF-25 (from ovine hypothalamus17), each of which consists of an N-terminal extension of SRIF-14. We now report that SRIF-28 and SRIF-25 are more potent than SRIF-14 in the inhibition of insulin release, but that SRIF-14 preferentially inhibits glucagon release. This suggests that SRIF-28 and SRIF-25 are not mere biosynthetic precursors of SRIF-14 and that their differential release may be physiologically important.

    Original languageEnglish (US)
    Pages (from-to)76-77
    Number of pages2
    JournalNature
    Volume291
    Issue number5810
    DOIs
    StatePublished - Dec 1 1981

    ASJC Scopus subject areas

    • General

    Fingerprint Dive into the research topics of 'Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion'. Together they form a unique fingerprint.

  • Cite this

    Mandarino, L., Stenner, D., Blanchard, W., Nissen, S., Gerich, J., Ling, N., Brazeau, P., Bohlen, P., Esch, F., & Guillemin, R. (1981). Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature, 291(5810), 76-77. https://doi.org/10.1038/291076a0